CeriBell (CBLL)

Traditional EEG testing can require specialized staff, bulky equipment, and delays that are difficult to manage in emergency departments, intensive care units, and other high-acuity settings. CeriBell addresses that gap with portable hardware that can be deployed at the bedside, paired with software and artificial intelligence tools that help clinicians identify concerning EEG patterns more quickly. The system is intended to support rapid assessment as well as ongoing monitoring of patients who may be at risk of non-convulsive seizures or status epilepticus.

The company’s product offering includes Point-of-Care EEG, Clarity, and the EEG Portal. Clarity uses AI-powered algorithms to help interpret EEG signals and alert care teams to seizure-related activity, while the portal supports access, review, and workflow integration for clinical users. The overall aim is not to replace neurologists, but to make neurological information available earlier in the care pathway and support more informed treatment decisions.

CeriBell operates in the broader medtech and digital health market, where hospitals are seeking tools that reduce diagnostic delays, improve patient triage, and make specialist-level data more accessible. CBLL offers investors exposure to a specialized neurology-focused device and software platform built for acute hospital care.